Table 9.
Comparative cardiac adverse event data for TPE in MG.
| References | Lal et al. (54) | Berrouschot et al. (53) | Gajdos et al. (41) | Barth et al. (5) | Qureshi et al. (42) | Köhler et al. (52) | Trikha et al. (65) | Mandawat et al. (1) | Guptill et al. (62) | Mandawat et al. (63) | Saeteng et al. (56) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment context | Acute | Acute | Acute | Acute | Acute | Acute | Acute | Mixed | Mixed | Mixed | Peri-op |
| Comparison | TPE/ | TPE/ | TPE/ | TPE/ | TPE / | TPE / | TPE QD/ | TPE/ | TPE peripheral/ | TPE early | TPE/ |
| No TPE** | No TPE** | IVIG | IVIG | IVIG | lA | TPE Q.AD | IVIG | TPE central* | TPE delayed | No TPE | |
| Timing | hosp. | NS | 15 days | 30 days | hosp. | Tx | hosp. | hosp. | Tx | hosp. | hosp. |
| # Patients | 4/3 | 21/42 | 41/46 | 41/40 | 28/26 | 10/9 | 16/17 | 1,269/340 | 100/34 | 870/183 | 33/53 |
| Cardiac complication (Unspecified) | - | - | - | - | 21/4% | - | - | 15/10%∧ | - | 12/25%∧ | - |
| Arrhythmia (Other/Unspecified) | 0/33% | 29/12% | - | - | - | 20/11% | - | - | 1/15%∧ | - | 0/0% |
| Tachycardia | - | - | 2/0% | - | - | 10/33% | 0/6% | - | - | - | - |
| Heart failure | - | - | - | 2/0% | - | 0/0% | - | - | - | - | - |
| Myocardial Infarction | - | - | - | 2/0% | - | - | - | - | - | - | - |
hosp., during hospitalization; Tx, during treatment period; lA, immunoadsorption; QD, daily; Q.AD, every other day; NS, not stated. No significant difference observed between treatments (p ≥ 0.05) unless noted.
∧
p < 0.05 as reported by original authors or calculated using Fisher exact test.
*
peripheral venous access and central venous access.